Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies

Mark M. Painter(Translational Therapeutics (United States)), Timothy S. Johnston(National Institutes of Health), Kendall A. Lundgreen(University of Pennsylvania), Jefferson Santos(University of Pennsylvania), Juliana S. Qin(University of Pennsylvania), Rishi R. Goel(Translational Therapeutics (United States)), Sokratis A. Apostolidis(Translational Therapeutics (United States)), Divij Mathew(Translational Therapeutics (United States)), Bria Fulmer(Translational Therapeutics (United States)), Justine C. Williams(University of Pennsylvania), Michelle L. McKeague(University of Pennsylvania), Ajinkya Pattekar(University of Pennsylvania), Ahmad Goode(University of Pennsylvania), Sean Nasta(University of Pennsylvania), Amy E. Baxter(Translational Therapeutics (United States)), Josephine R. Giles(Parker Institute for Cancer Immunotherapy), Ashwin N. Skelly(University of Pennsylvania), Laura E Felley(University of Michigan), M. A. McLaughlin(Translational Therapeutics (United States)), JoEllen Weaver(University of Pennsylvania), Penn Medicine BioBank(Translational Therapeutics (United States)), Oliva Kuthuru(Translational Therapeutics (United States)), Jeanette Dougherty(University of Pennsylvania), Sharon Adamski(University of Pennsylvania), Sherea Long(University of Pennsylvania), Macy Kee(University of Pennsylvania), Cynthia Clendenin(La Jolla Institute for Immunology), Ricardo da Silva Antunes(La Jolla Institute for Immunology), Alba Grifoni(La Jolla Institute for Immunology), Daniela Weiskopf(La Jolla Institute for Immunology), Alessandro Sette(La Jolla Institute for Immunology), Alexander C. Huang(Parker Institute for Cancer Immunotherapy), Daniel J. Rader(University of Pennsylvania), Scott E. Hensley(University of Pennsylvania), Paul Bates(Translational Therapeutics (United States)), Allison R. Greenplate(Parker Institute for Cancer Immunotherapy), E. John Wherry(Parker Institute for Cancer Immunotherapy)
bioRxiv (Cold Spring Harbor Laboratory)
February 6, 2023
Cited by 8Open Access
Full Text

Abstract

SARS-CoV-2 infection of vaccinated individuals is increasingly common but rarely results in severe disease, likely due to the enhanced potency and accelerated kinetics of memory immune responses. However, there have been few opportunities to rigorously study early recall responses during human viral infection. To better understand human immune memory and identify potential mediators of lasting vaccine efficacy, we used high-dimensional flow cytometry and SARS-CoV-2 antigen probes to examine immune responses in longitudinal samples from vaccinated individuals infected during the Omicron wave. These studies revealed heightened Spike-specific responses during infection of vaccinated compared to unvaccinated individuals. Spike-specific CD4 T cells and plasmablasts expanded and CD8 T cells were robustly activated during the first week. In contrast, memory B cell activation, neutralizing antibody production, and primary responses to non-Spike antigens occurred during the second week. Collectively, these data demonstrate the functionality of vaccine-primed immune memory and highlight memory T cells as rapid responders during SARS-CoV-2 infection.


Related Papers

No related papers found

Powered by citation graph analysis